Asad Bashey
Overview
Explore the profile of Asad Bashey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
4310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dehn J, Logan B, Shaw B, Devine S, Ciurea S, Horowitz M, et al.
medRxiv
. 2024 Oct;
PMID: 39371123
Importance: Patients requiring allogeneic hematopoietic cell transplantation have variable likelihoods of identifying an 8/8 HLA-matched unrelated donor. A Search Prognosis calculator can estimate the likelihood. Objective: To determine if using...
2.
Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro R, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1139-1154.
PMID: 39260570
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft....
3.
Solh M, Aubrey M, Zhang X, Bashey A, Freed B, Roark C, et al.
Bone Marrow Transplant
. 2024 Jul;
59(10):1433-1439.
PMID: 39085372
Graft versus tumor relies on tumor-associated antigens (TAAs) that are presented to donor T cells via human leukocyte antigens (HLAs). The HLA evolutionary divergence (HED) between alleles of a single...
4.
Solomon S, Bachier-Rodriguez L, Bashey A, Zhang X, Jackson K, Holland H, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):903.e1-903.e9.
PMID: 38879167
Following conventional graft-versus-host disease (GVHD) prophylaxis, the development of acute and/or chronic GVHD is associated with lower relapse rates. However, the effects of GVHD on relapse and non-relapse mortality following...
5.
Solomon S, Aubrey M, Bachier-Rodriguez L, Solh M, Jackson K, Zhang X, et al.
Transplant Cell Ther
. 2024 Apr;
30(6):608.e1-608.e10.
PMID: 38561140
The presence of an HLA-DPB1 nonpermissive mismatch (NPMM) by the TCE-3 model has been associated with improved survival following haploidentical donor transplantation (HIDT) using post-transplantation cyclophosphamide (PTCy). With the development...
6.
Solh M, Bashey A, Zhang X, Holland H, Bachier-Rdriguez L, Morris L, et al.
Transplant Cell Ther
. 2024 Mar;
30(6):607.e1-607.e8.
PMID: 38552844
The development of chronic graft-versus-host disease (GVHD) in 1-year survivors after matched related or unrelated hematopoietic cell transplantation was shown to be associated with higher nonrelapse mortality (NRM) and worse...
7.
McCarthy P, Attwood K, Liu X, Chen G, Minderman H, Alousi A, et al.
Bone Marrow Transplant
. 2023 Dec;
59(3):334-343.
PMID: 38110620
Identifying plasma biomarkers early after allo-HCT may become crucial to prevent and treat severe aGvHD. We utilized samples from 203 allo-HCT patients selected from the Blood & Marrow Transplant Clinical...
8.
Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, et al.
Blood Adv
. 2023 Aug;
7(21):6492-6505.
PMID: 37647601
Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy....
9.
Jain T, Tsai H, Elmariah H, Vachhani P, Karantanos T, Wall S, et al.
Haematologica
. 2023 Jul;
108(12):3321-3332.
PMID: 37408464
Haploidentical donors offer a potentially readily available donor, especially for non-White patients, for hematopoietic cell transplantation (HCT). In this North American collaboration, we retrospectively analyzed outcomes of first HCT using...
10.
Solomon S, Solh M, Morris L, Holland H, Bachier-Rodriguez L, Zhang X, et al.
Blood Adv
. 2023 Jun;
7(18):5215-5224.
PMID: 37379271
Allogeneic transplant remains the best postremission therapy for patients with nonfavorable risk acute myeloid leukemia (AML). However, some patients are ineligible because of psychosocial barriers, such as lack of appropriate...